Mark Lebwohl, MD, and Jerry Bagel, MD, MS, provide an overview of the pathogenesis of and comorbidities associated with plaque psoriasis.

Linda F. Stein Gold, MD, delves into the psychosocial impacts of living with plaque psoriasis.

Leon Kircik, MD, and Jerry Bagel, MD, MS, explain their reasoning behind choosing whether a patient with plaque psoriasis is a candidate for either topical or systemic therapeutic agents.

The panel addresses their treatment practices and procedure when first seeing a patient with plaque psoriasis, as well as the role of topical therapy in this disease.

Spearheaded by Dr Bagel, the panel explores the role of phototherapy in the treatment of plaque psoriasis.

Mark Lebwohl, MD, and Jerry Bagel, MD, MS, review the currently available TNF-α and IL-12/23 inhibitors used to treat plaque psoriasis.

Dr Kircik discusses the mechanisms of action involving IL-17 inhibitors when using them as a first-line therapy for plaque psoriasis.

Dr Lebwohl explains the contraindications for IL-23 inhibitors when using them to treat plaque psoriasis.

Drs Kircik and Stein Gold address roflumilast and tapinarof as new topical agents for the management of plaque psoriasis.

Dr Lebwohl provides insight on a new class of agents, the TYK2 inhibitors.

Jerry Bagel, MD, MS, provides and overview of the phase 3 POETYK PSO-1 and POETYK PSO-2 trials, while Leon Kircik, MD, reviews the efficacy and safety of each of them.

Drs Bagel and Lebwohl discuss the new biologic agent, bimekuzumab, and the data results from the phase 3 BE READY trial.

The panel each list challenges and unmet needs faced when managing the treatment of plaque psoriasis.

The panel ponders how they will incorporate the discussed new agents into their plaque psoriasis treatment processes.

Dr Lebwohl concludes by giving advice to community physicians and dermatologist on what they can do to improve treating patients with plaque psoriasis.